Innate Killer Summit 2019

Memo

The Innate Killer Summit 2019 discusses safer, more cost-effective and potentially more efficacious NK cell immunotherapy as the next generation of frontline cancer therapy. It will help you to optimize your manufacturing and process development strategies to further reduce the cost of off-the-shelf NK cell therapies. Discuss the most up to date clinical data on genetically engineered NK cells from CARs to bispecific engagers and ensure persistence and durability. Bringing together over 100 of the field's leading minds to share experience and knowledge on the optimal NK cell source and improve the efficacy of NK cell therapies through enhanced targeting methods. Join us at the 4th Annual Innate Killer Summit to bring to patients the next generation of cell immunotherapies that are safer and cheaper. Brochure: https://go.evvnt.com/314495-2?pid=5569 Time: 08:00 to 17:00. Venue details: Hilton San Diego Gaslamp Quarter, 401 K Street, San Diego, 92101, United States. Prices: Conference Only: USD 2899.0,Conference + 2 Workshops: USD 3897.0. Speakers: Sonny Hsiao CEO, President and Co-Founder Acepodia Inc., Martin Treder, CSO, Affimed, Robin Parihar, Assistant Professor of Pediatric Hematology- Oncology, Baylor College of Medicine, Xiaokui Zhang, CSO, Celularity, Robert Hariri, Chairman and CEO, Celularity, Noah Merin, Assistant Professor, Cedars-Sinai Medical Center, Robert Igarashi, CSO, Cyto-Sen Therapeutics, Emily Mace, Assistant Professor of Pediatrics, Columbia University, Rizwan Romee, Director of Haploidentical Donor Transplant Program, Dana-Farber Cancer Institute, Bob Valamehr, CDO, Fate Therapeutics, Amir Horowitz, Assistant Professor of Oncological Sciences, Ichan School of Medicine, Mark Lowdell, CSO, ImmuneBio Inc, Lawrence Lamb, Chair of the Scientific Advisory Board, Incysus Therapeutics Inc., Evren Alici, Assistant Professor of Hematology, Karolinska Institutet, Lotte Wieten, Department Head of Transplantation Immunology, Maastricht University, Patrick Soon-Shiong, Founder and CEO, NantWorks, James Trager, Senior Vice President of Research and Development, Nkarta Therapeutics, Stacey Cranert, Research Scientist, Poseida Therapeutics, Alicja Copik, Research Assistant Professor, Burnett School of Biomedical Sciences, Anahid Jewett ,Professor and Director of Tumor Immunology Laboratory, UCLA School of Dentistry and Medicine